Hepatology COVID-19 Registry Week 15 Report 2 New Cases Added to the Report Since Week 13 Liver Disease, Non-Transplant

Hepatology COVID-19 Registry Week 15 Report 2 new cases added to the report since week 13

Liver disease, Non-Transplant (N=26) Post-liver transplantation (N=24) Gender (%) Female = 10 (38.5 %) Female = 11 (45.8 %) Male = 16 (61.5 %) Male = 13 (54.2 %) Median Age (yr) at time of COVID 6.5 (0.16-20) 13 (0.5-21) diagnosis (range) Etiology of liver disease Biliary atresia = 7 Biliary atresia = 8 NAFLD = 5 Acute liver failure = 6 Autoimmune hepatitis = 5 Metabolic disorders = 3 Acute Liver Failure = 2 Tumor = 2 Metabolic disorder = 2 Others** = 5 Others* = 5 Highest level of care Outpatient 7 17 Hospital floor 10 3 ICU 9 4 Immunosuppression at time No Immunosuppression = 21 Tacrolimus = 20 of COVID diagnosis Azathioprine = 5 Steroids = 10 (*some patients were on multiple Steroids =3 Mycophenolate Mofetil = 9 agents) Sirolimus = 3 Azathioprine = 1 Cyclosporine =1 Specific Treatment for COVID IVIG = 4 Hydroxychloroquine = 2 (*some patients were on multiple Hydroxychloroquine + Azithromycin = 3 Convalescent Plasma = 2 agents) Steroids = 3 Azithromycin = 1 Remdesivir = 2 IVIG = 1 Tocilizumab + Sarilumab = 2 Favipiravir = 1 Eculizimab = 2 Remdesivir = 1 Convalescent Plasma = 1 Steroid (Dexamethasone) = 1 Anakinra = 1

Highest respiratory support None 18 21 Nasal cannula/CPAP/BiPAP 3 2 Mechanical ventilation 4 0 High Frequency Oscillatory 1 0 ventilation Pending information - 1 Final clinical outcome Death 1*** 0 Recovery 22 20 Still active in clinical course 2 3 Pending information 1 1 Liver related Complications Ascites = 7 - Portal Hypertension Bleeding =1 Infection = 1 *Others CLD: idiopathic cholestasis, GVHD/vanishing bile duct syndrome (Post BMT), IFALD with biliary obstruction, PFIC ** Others PLT: IFALD , Congenital hepatic fibrosis, AIH-Sclerosing cholangits ***Pulmonary hemorrhage, multi-organ failure Three recipients had multivisceral transplantation; One PLT recipient also had a transplanted kidney. Page 1 of 2

Presenting symptoms at time of diagnosis Change done to Immunosuppressive agent (Post LT)

*Constitutional symptoms reported: Loss of smell/taste , fever, myalgia, fatigue, sore throat # Other symptoms reported: Malaise, anorexia, headache, rash, Kawasaki disease like *Stopped, decreased the dose, others and No changes presentation(MIS-C) Commonest agent stopped: Mycophenolate Mofetil